



Acarix and Aalborg University Abstract Accepted for AHA 2025

Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that our abstract on the Heart Failure (HF) Seismo algorithm, developed in collaboration with Aalborg University Hospital Department of Cardiology, has been accepted for presentation at the American Heart Association Congress in November 2025.

This marks an exciting milestone as we showcase the potential of our Any (HFpEF or HFrEF) HF diagnostic, designed to deliver the same rapid, point-of-care assessment as our established CADScor® device.

"We look forward to highlighting how this innovation can help advance early detection and management of Heart Failure, ultimately supporting better patient outcomes." — CEO Aamir Mahmood

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[Acarix and Aalborg University Abstract Accepted for AHA 2025](#)